Emisphere Technologies

(EMIS, PINK)

$7.81

+$0.01
(+0.00%)
PE Ratio
0.00
EPS
-$0.0980
Market Cap
$498M
52 Week Range
$5.00 - $1.2K
Operating Margin
-595.59%
Dividend & Yield
$0 (0.00%)
Volume
NaN
Rev. per Share
$0.0170

About Emisphere Technologies

Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.

Earnings

News about Emisphere Technologies

Emisphere Technologies

Type
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App

Trading involves significant risk of loss. It is not suitable for all investors and you should make sure you understand the risks involved, seeking independent advice if necessary.

Never risk more than you are willing to lose. Trading futures and other derivatives may cause losses that exceed deposits.

Hypothetical performance results have inherent limitations, some of which are described below. Kinfo makes no representation that any trading account will or is likely to achieve profits or losses like those shown. There are often sharp differences between hypothetical trading performance results and the actual results subsequently achieved by any trading program. Past results of advertised trading systems, profit statements, charts or any other representations are not indicative of future performance.

Kinfo is an educational site and is not a financial adviser or broker. All stocks, ETFs, commodities, Indices, Forex, Bonds, and other securities mentioned in our courses are for educational and illustrative purposes only. If you need professional investment advice, please consult a registered investment adviser. Futures and Options carry risk and may not be suitable for everyone.

Kinfo demonstrates specific advanced approaches (or methods). Any mention of Return of Investment percentages is only indicative of the potential of the strategy or the system and is not meant to signify any guaranteed returns.

Success in trading involves a range of human factors like decision making skills, adjustment skills, emotional control, and risk management and other psychological and behavioral parameters, all of which are completely in the hands of the individual. Trading involves significant risk of loss. It is not suitable for all investors.

Charts on kinfo provided by TradingView